SEC Company Response from Lite Strategy, Inc. (LITS) (CIK 0001262104) (LITS) — May 11, 2017
Lite Strategy, Inc. (LITS) (CIK 0001262104)
Date: May 11, 2017 · CIK: 0001262104 · Accession: 0001193125-17-166791
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-217645
Letter
MEI Pharma, Inc.
11975 El Camino Real, Suite 101
San Diego, CA 92130
May 11, 2017
VIA EDGAR TRANSMISSION
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention:
Suzanne Hayes, Assistant Director, Office of Healthcare and Insurance
Mary Beth Breslin
Christine Westbrook
Re:
MEI Pharma, Inc.
Registration Statement on Form S-3
Filed May 4, 2017
File No. 333-217645
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, MEI Pharma, Inc. (the “Company”), hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-217645), so that such registration statement may become effective at 4:00 p.m. (Washington, D.C. time) on May 15, 2017, or as soon as practicable thereafter.
In connection with this request, the Company acknowledges that:
•
should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for adequacy and accuracy of the disclosure in the filing; and
•
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
MEI PHARMA, INC.
By:
/s/ Brian G. Drazba
Name:
Brian G. Drazba
Title:
Chief Financial Officer
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
MEI Pharma, Inc.
11975 El Camino Real, Suite 101
San Diego, CA 92130
May 11, 2017
VIA EDGAR TRANSMISSION
Securities and Exchange
Commission
Division of Corporation Finance
100 F Street,
N.E.
Washington, D.C. 20549
Attention:
Suzanne Hayes, Assistant Director, Office of Healthcare and Insurance
Mary Beth Breslin
Christine Westbrook
Re:
MEI Pharma, Inc.
Registration Statement on Form S-3
Filed May 4, 2017
File No. 333-217645
Ladies and Gentlemen:
Pursuant
to Rule 461 under the Securities Act of 1933, as amended, MEI Pharma, Inc. (the “Company”), hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-217645), so that such registration statement may become effective at 4:00 p.m. (Washington, D.C. time) on May 15, 2017, or as soon as practicable thereafter.
In connection with this request, the Company acknowledges that:
•
should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action
with respect to the filing;
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for adequacy and accuracy of the disclosure
in the filing; and
•
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
MEI PHARMA, INC.
By:
/s/ Brian G. Drazba
Name:
Brian G. Drazba
Title:
Chief Financial Officer